A Single Centre, Two-part, Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects

Trial Profile

A Single Centre, Two-part, Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs MMV 390048 (Primary)
  • Indications Falciparum malaria
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 07 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 16 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jan 2017.
    • 16 Jan 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top